MYD vs CSTL Comparison

Blackrock Muniyield Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes. The fund invests a majority of its assets in municipal bonds exempt from U.S. federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax). These bonds are predominantly long-term (with a maturity of more than ten years at the time of investment), and rated as investment grade, or deemed to be of comparable quality by the investment adviser at the time of investment. The fund can also invest directly in such securities or synthetically through the use of derivatives.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.